These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 1086910

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J.
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [Abstract] [Full Text] [Related]

  • 3. Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.
    Weiss HJ, Rogers J, Brand H.
    J Clin Invest; 1973 Nov; 52(11):2697-707. PubMed ID: 4201262
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM.
    Wien Klin Wochenschr; 1982 Oct 15; 94(19):509-14. PubMed ID: 6818773
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.
    Hillarp A, Friedman KD, Adcock-Funk D, Tiefenbacher S, Nichols WL, Chen D, Stadler M, Schwartz BA.
    Haemophilia; 2015 Nov 15; 21(6):837-45. PubMed ID: 26172561
    [Abstract] [Full Text] [Related]

  • 11. Failure of AHF concentration to control bleeding in von Willebrand's disease.
    Green D, Potter EV.
    Am J Med; 1976 Mar 15; 60(3):357-60. PubMed ID: 1083144
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.
    Semin Thromb Hemost; 2006 Sep 15; 32(6):636-45. PubMed ID: 16977574
    [Abstract] [Full Text] [Related]

  • 15. Plasma collagen cofactor correlates with von Willebrand factor antigen and ristocetin cofactor but not with bleeding time.
    Aihara M, Kimura A, Chiba Y, Yoshida Y.
    Thromb Haemost; 1988 Jun 16; 59(3):485-90. PubMed ID: 3142084
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease.
    Favaloro EJ, Thom J, Patterson D, Just S, Baccala M, Dixon T, Meiring M, Koutts J, Rowell J, Baker R.
    Blood Coagul Fibrinolysis; 2009 Sep 16; 20(6):475-83. PubMed ID: 19584715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.